Amid biotechs’ cash crunch, asset marketplace 9xchange poised to speed deals

Anat Naschitz founded asset marketplace 9xchange with the conviction that there could be a better way for biopharmas to identify assets that would prosper in a different company’s hands, and start the dialogue to forge deals. Months into its launch, 9exchange is now adding tools to enhance the service via a partnership with BenevolentAI.

Naschitz, a co-founder of OrbiMed Advisers’ Israel operation with experience in spinning out programs that weren’t moving forward within other biopharmas’ walls, told BioCentury that the current cash-crunch environment will likely magnify the need for assets to find new homes. Smaller biotechs may also not have the business development resources to fully explore partnerships...